trending Market Intelligence /marketintelligence/en/news-insights/trending/M3vf3qj997oNNOBmXLdafA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Report: Gilead, GlaxoSmithKline mulling bids for United Therapeutics

Blog

JMP Securities is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

M&A rebound sparks optimism for near-term deal activity

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition


Report: Gilead, GlaxoSmithKline mulling bids for United Therapeutics

Gilead Sciences Inc. and GlaxoSmithKline plc are among suitors weighing bids for United Therapeutics Corp., the Evening Standard reported Aug. 4, citing anonymous sources.

The news outlet reported that Gilead is most likely to win a bid, while Novartis AG is another possible contender. According to the anonymous sources, United could be worth as much as $200 per share in a sale, making the purchase price around $8.7 billion.

GSK is being advised by Lazard and Citi in the process, the Evening Standard reported.